What is a clinically significant donor-specific antibody before lung transplantation?
American Journal of Transplantation · 2023
DOI: 10.1016/j.ajt.2023.06.005 ↗Kurz gefasst
Editorial in der Zeitschrift American Journal of Transplantation, 2023. Verfasst von Ramsey R Hachem und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. Electronic address: rhachem@wus…. Hauptthemen laut MEDLINE: Antibodies, Lung Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In 1969, Patel and Terasaki1Patel R. Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation.N Engl J Med. 1969; 280: 735-739https://doi.org/10.1056/NEJM196904032801401Crossref PubMed Scopus (1285) Google Scholar demonstrated the role of crossmatching in solid-organ transplantation. In this landmark study, 24 of 30 kidney transplant recipients who had a positive crossmatch had immediate graft failure, demonstrating that cytotoxic donor-specific antibodies (DSAs) are a strong contraindication to transplantation.1Patel R. Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation.N Engl J Med. 1969; 280: 735-739https://doi.org/10.1056/NEJM196904032801401Crossref PubMed Scopus (1285) Google Scholar Since then, methods to identify human leukocyte antigen (HLA) antibodies and their specificities have improved significantly, and the widespread use of the virtual crossmatch has made hyperacute rejection exceedingly rare. However, sensitive antibody detection assays such as single antigen bead assay identify more allosensitized patients, but it has become increasingly clear that not all HLA antibodies have the same deleterious effect on the allograft. This emphasizes the importance of close collaboration between clinicians and the HLA laboratory in managing allosensitized patients. In this issue of the Journal, 2 large transplant programs report successful experiences with different regimens to facilitate transplantation in allosensitized patients.2Aversa M. Kiernan J. Martinu T. et al.Outcomes following flow-cytometry crossmatch-positive lung transplants managed with peri-operative desensitization.Am J Transplant. 2023; https://doi.org/10.1016/j.ajt.2023.04.033Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar,3Heise EL, Chichelnitskiy E, Greer M, et al. Lung transplantation despite preformed donor-specific anti-HLA antibodies: 9-year single-center experience. Am J Transplant, in press.Google Scholar The Toronto Lung Transplant Program previously reported successful outcomes in transplanting patients with preformed DSA with a perioperative desensitization regimen consisting of plasma exchange (PLEX), antithymocyte globulin (ATG), and intravenous immune globulin (IVIG).4Tinckam K.J. Keshavjee S. Chaparro C. et al.Survival in sensitized lung transplant recipients with perioperative desensitization.Am J Transplant. 2015; 15: 417-426https://doi.org/10.1111/ajt.13076Abstract Full Text Full Text PDF PubMed Scopus (119) Google Scholar However, this initial experience did not include flow cytometry crossmatch (FCXM) testing, and only a small number of patients with preformed DSA had positive complement-dependent cytotoxicity (CDC) crossmatch.4Tinckam K.J. Keshavjee S. Chaparro C. et al.Survival in sensitized lung transplant recipients with perioperative desensitization.Am J Transplant. 2015; 15: 417-426https://doi.org/10.1111/ajt.13076Abstract Full Text Full Text PDF PubMed Scopus (119) Google Scholar In the current study, FCXM testing was performed, and patients were stratified based on the results.2Aversa M. Kiernan J. Martinu T. et al.Outcomes following flow-cytometry crossmatch-positive lung transplants managed with peri-operative desensitization.Am J Transplant. 2023; https://doi.org/10.1016/j.ajt.2023.04.033Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar There was no significant difference in chronic lung allograft dysfunction-free survival or overall survival between patients who had preformed DSA and positive FCXM, those who had preformed DSA and negative FCXM, and those who did not have preformed DSA when those with preformed DSA were treated with intraoperative PLEX followed by ATG and IVIG.2Aversa M. Kiernan J. Martinu T. et al.Outcomes following flow-cytometry crossmatch-positive lung transplants managed with peri-operative desensitization.Am J Transplant. 2023; https://doi.org/10.1016/j.ajt.2023.04.033Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar Of note, 33% of those with preformed DSA who had a negative FCXM and 23% of those with preformed DSA who had a positive FCXM did not receive ATG induction. It should be noted that the threshold for a positive FCXM in the center’s histocompatibility laboratory is comparable to a median channel shift of 96 for T cells and 105 for B cells. Although these are typical thresholds used in many histocompatibility laboratories, they are weakly positive and would not result in a positive CDC crossmatch. In a separate study, the Hannover Lung Transplant Program reported their results with desensitization using immunoglobulin A (IgA)- and IgM-enriched IVIG in combination with PLEX, or immunoadsorption, and rituximab.3Heise EL, Chichelnitskiy E, Greer M, et al. Lung transplantation despite preformed donor-specific anti-HLA antibodies: 9-year single-center experience. Am J Transplant, in press.Google Scholar In this protocol, PLEX is started before transplant and continued for 3 days, followed by IgA- and IgM-enriched IVIG and a single dose of rituximab. DSA was defined using a threshold mean fluorescence intensity of 1000, and the median DSA mean fluorescence intensity was 4146 among those with preformed DSA. Importantly, 23% of those with preformed DSA did not have detectable circulating DSA at the time of transplant. Outcomes of patients who had preformed DSA were compared to those who did not have preformed DSA before transplantation and did not develop DSA in the early period after transplantation. Outcomes of patients who developed early DSA were not reported in this study; this was a missed opportunity as early DSA in these patients likely represents a memory response similar to those who had preformed DSA, and that comparison may have provided additional insights into the role of the desensitization regimen. There was no significant difference in graft survival or freedom from chronic lung allograft dysfunction between those who had preformed DSA and those who did not develop early DSA after transplant. Among 62 patients with preformed DSA, 7 had a positive CDC crossmatch, but there was no difference in posttransplant outcomes between these 7 and the remainder of those who had preformed DSA. Though these centers’ innovative strategies to improve access to transplantation are commendable, it is important to note that these approaches do not distinguish or recognize the different risks associated with different DSAs before transplant. Indeed, the positive FCXM results in the Toronto experience are weak and would not be expected to result in a positive CDC crossmatch or cause hyperacute rejection. Likewise, only a small minority of DSAs in the Hannover experience resulted in a positive CDC crossmatch. In the age of precision medicine, risk stratification is crucial, particularly when implementing treatments that may be associated with toxicity. A multidisciplinary working group of experts reviewed the literature regarding HLA antibody assessment and its use in clinical practice before and after transplantation.5Tambur A.R. Campbell P. Claas F.H. et al.Sensitization in Transplantation: assessment of risk (STAR) 2017 Working Group Meeting Report.Am J Transplant. 2018; 18: 1604-1614https://doi.org/10.1111/ajt.14752Abstract Full Text Full Text PDF PubMed Scopus (188) Google Scholar The consensus recommendations to avoid the limitations of single antigen bead assay testing were to incorporate DSA characterization (eg, measuring titer and/or complement-activating capacity) and the number of DSA and subclass specificities to improve risk stratification and better define clinically significant DSA before transplantation and the associated risk of rejection. Ideally, such an approach would be tested in the context of multicenter clinical studies. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. Outcomes after flow cytometry crossmatch-positive lung transplants managed with perioperative desensitizationAmerican Journal of TransplantationVol. 23Issue 11PreviewOur program previously reported successful outcomes following virtual crossmatch (VXM)–positive lung transplants managed with perioperative desensitization, but our ability to stratify their immunologic risk was limited without flow cytometry crossmatch (FCXM) data before 2014. The aim of this study was to determine allograft and chronic lung allograft dysfunction (CLAD)–free survival following VXM-positive/FCXM-positive lung transplants, which are performed at a minority of programs due to the high immunologic risk and lack of data on outcomes. Full-Text PDF Lung transplantation despite preformed donor-specific antihuman leukocyte antigen antibodies: a 9-year single-center experienceAmerican Journal of TransplantationVol. 23Issue 11PreviewPretransplant allosensitization to human leukocyte antigens (HLA) increases the recipient’s waiting list time and mortality in lung transplantation. Rather than waiting for crossmatch-negative donors, since 2013, recipients with preformed donor-specific antiHLA antibodies (pfDSA) have been managed with repeated IgA- and IgM-enriched intravenous immunoglobulin (IgGAM) infusions, usually in combination with plasmapheresis before IgGAM and a single dose of antiCD20 antibody. This retrospective study presents our 9-year experience with patients transplanted with pfDSA. Full-Text PDF Open Access
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. Electronic address: rhachem@wustl.edu.
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Zitieren
APA
Hachem, R. R., & Zeevi, A. (2023). What is a clinically significant donor-specific antibody before lung transplantation?. American Journal of Transplantation. https://doi.org/10.1016/j.ajt.2023.06.005
Vancouver
Hachem RR, Zeevi A. What is a clinically significant donor-specific antibody before lung transplantation?. American Journal of Transplantation. 2023. doi:10.1016/j.ajt.2023.06.005
BibTeX
@article{Hachem2023,
author = {Hachem, Ramsey R and Zeevi, Adriana},
title = {What is a clinically significant donor-specific antibody before lung transplantation?},
journal = {American Journal of Transplantation},
year = {2023},
doi = {10.1016/j.ajt.2023.06.005}
}
EUVIMED